Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 761780 of 20,252 grants

Active NON-SBIR/STTR RPGS
Developing a novel agonist of CD137 for cancer immunoprevention
NATIONAL CANCER INSTITUTE University of Missouri-Columbia United States 2024 – 2026

PROJECT SUMMARY The primary objective of this proposal is to assess a novel agonist of 4-1BB costimulatory pathway, SA-4-1BBL, as a single agent for cancer immunoprevention in prec...

$7.61M
USD
Active NON-SBIR/STTR RPGS
High-risk hepatoblastoma dissemination control by oncogenic NRF2
NATIONAL CANCER INSTITUTE Baylor College of Medicine United States 2024 – 2029

Hepatoblastoma (HB) is the most common liver tumor in children, believed to have the fastest rising incidence of all pediatric solid tumors. Unfortunately, HB has a poor overall su...

$4.48M
USD
Completed OTHER RESEARCH-RELATED
CSHL 2024 Mechanisms & Models of Cancer Conference
NATIONAL CANCER INSTITUTE Cold Spring Harbor Laboratory United States 2024 – 2025

COLD SPRING HARBOR LABORATORY CONFERENCE MECHANISMS AND MODELS OF CANCER August 13-17, 2024 Recent years have produced transformative discoveries that have revealed the mechanisms...

$200K
USD
Active NON-SBIR/STTR RPGS
mHealth Intervention to Support Symptom Communication for Children with Cancer
NATIONAL CANCER INSTITUTE University of Utah United States 2024 – 2029

PROJECT SUMMARY Inadequately managed symptoms caused by their disease and its treatment result in unnecessary suffering for children with cancer that interferes with their quality...

$5.64M
USD
Active NON-SBIR/STTR RPGS
Title: Multi-Site Randomized Controlled Trial of a Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
NATIONAL CANCER INSTITUTE Massachusetts General Hospital United States 2024 – 2029

PROJECT SUMMARY/ABSTRACT Overview: The goal of this study is to examine the efficacy of a novel digital application (SHIFT) for improving sexual health outcomes, quality of life (Q...

$6.03M
USD
Active OTHER RESEARCH-RELATED
Preference-Based Treatment Valuation in Low-Risk Thyroid Cancer
NATIONAL CANCER INSTITUTE University of Maryland Baltimore United States 2024 – 2028

Summary/Abstract: This Career Development Award (K08) establishes health state utilities across several established and evolving therapies for low-risk, sub-centimeter thyroid canc...

$2.79M
USD
Active NON-SBIR/STTR RPGS
Role of JMJD4 in Pancreatic Cancer
NATIONAL CANCER INSTITUTE University of Oklahoma Hlth Sciences Ctr United States 2024 – 2026

PROJECT SUMMARY – Role of JMJD4 in Pancreatic Cancer In 2023, nearly 50,000 patients will die from pancreatic cancer in the US. This malignancy has one of the worst survival rates,...

$1.45M
USD
Active NON-SBIR/STTR RPGS
Engineering synthetic feedback control in T cell signaling for anti-tumor immunity
NATIONAL CANCER INSTITUTE University of Washington United States 2024 – 2029

Project Summary Engineered T cells are emerging as promising therapeutic agents against a wide variety of cancers. However, despite remarkable success against blood cancers, these...

$6.42M
USD
Completed OTHER RESEARCH-RELATED
Leveraging small molecule inhibitors to improve CD19 CAR T cell immunotherapy for KMT2A-rearranged ALL
NATIONAL CANCER INSTITUTE Children'S Hosp of Philadelphia United States 2024 – 2024

PROJECT SUMMARY/ABSTRACT This K08 mentored career development award proposal details a research and training plan that is designed to facilitate the career development and transiti...

$239.2K
USD
Active OTHER RESEARCH-RELATED
A Nurse-Led, Coping and Supportive Care Intervention to Improve Psychosocial Outcomes of Patients with Triple-Negative Breast Cancer During the Transition from Curative Therapy to Surveillance
NATIONAL CANCER INSTITUTE Massachusetts General Hospital United States 2024 – 2029

PROJECT SUMMARY/ABSTRACT Patients with triple-negative breast cancer (TNBC) account for approximately 15% of all breast cancer diagnoses but are disproportionately burdened with me...

$2.52M
USD
Active NON-SBIR/STTR RPGS
Multivalent Small Circular mRNA Vaccines for Melanoma Combination Immunotherapy
NATIONAL CANCER INSTITUTE University of Michigan At Ann Arbor United States 2024 – 2029

Abstract Melanoma is the most serious type of skin cancer. Although immune checkpoint blockade (ICB) therapy has benefited many melanoma patients, most patients do not respond to c...

$5.77M
USD
Active NON-SBIR/STTR RPGS
Macropinocytosis Inhibition as a Glutamine Mimetic Sensitization Strategy in Pancreatic Cancer
NATIONAL CANCER INSTITUTE Sanford Burnham Prebys Medical Discovery... United States 2024 – 2029

PROJECT SUMMARY Pancreatic ductal adenocarcinoma (PDAC) cells depend on glutamine to meet their unique metabolic needs. Glutamine fuels a wide array of biosynthetic pathways; howev...

$5.61M
USD
Active TRAINING, INDIVIDUAL
Translation Regulation Contributes to Hypoxia Adaptation in Glioblastoma
NATIONAL CANCER INSTITUTE Case Western Reserve University United States 2024 – 2028

PROJECT SUMMARY Glioblastoma (GBM) is a CNS tumor derived from glial cells. It is the most common and fatal primary malignant brain tumor in adults with a median survival of 15 mon...

$539.7K
USD
Active NON-SBIR/STTR RPGS
Dissecting and Targeting MAST1 Signaling in chemoresistant Cancers
NATIONAL CANCER INSTITUTE Emory University United States 2024 – 2029

PROJECT SUMMARY Platinum drugs such as cisplatin serve as a mainstay of cancer therapy, but resistance limits their curative potential. Through a kinome-wide RNAi screen, we identi...

$4.34M
USD
Active NON-SBIR/STTR RPGS
S1PR1-targeted PET imaging to predict and monitor response to HER2-targeting antibody-drug conjugates
NATIONAL CANCER INSTITUTE Washington University United States 2024 – 2026

PROJECT SUMMARY/ABSTRACT – In patients with gastric cancers who are clinically classified as HER2- positive, antibody-drug conjugates (ADC) prolong progression-free and overall sur...

$4M
USD
Active OTHER RESEARCH-RELATED
Quantitative characterization of tumor heterogeneity using habitat imaging for the prediction of patient outcome in triple negative breast cancer
NATIONAL CANCER INSTITUTE University of Washington United States 2024 – 2026

PROJECT SUMMARY The overall goal of this training proposal is to employ quantitative imaging to noninvasively characterize tumor microenvironmental heterogeneity in triple negative...

$1.01M
USD
Active NON-SBIR/STTR RPGS
Variant to Function Mapping of B-ALL Risk Loci
NATIONAL CANCER INSTITUTE Boston Children'S Hospital United States 2024 – 2029

ABSTRACT Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and arises predominantly from developing B-cell precursors. B-cell ALL (B-ALL) remains a leading...

$6.95M
USD
Active NON-SBIR/STTR RPGS
Characterization of Diverse Pediatric Cancers in LMIC Using Low-Cost Nanopore Sequencing
NATIONAL CANCER INSTITUTE University of North Carolina Chapel Hill United States 2024 – 2029

Project Summary / Abstract Virtually fatal 60-years ago, pediatric cancers are now curable for 85% of children who have access to contemporary treatments and robust supportive care...

$6.28M
USD
Completed NON-SBIR/STTR RPGS
Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors
NATIONAL CANCER INSTITUTE University of Iowa United States 2024 – 2025

PROJECT SUMMARY/ABSTRACT Peptide receptor radionuclide therapy (PRRT) with [177Lu]DOTATATE improves quality of life and survival in patients with advanced neuroendocrine tumors; ho...

$1.67M
USD
Active NON-SBIR/STTR RPGS
Monitoring Listeria in vivo using 18FDG and PET scan
NATIONAL CANCER INSTITUTE Albert Einstein College of Medicine United States 2024 – 2026

ABSTRACT Recently, our lab developed a novel immune therapeutic approach delivering TT as a neoantigen surrogate selectively into tumors by Listeria infection in vivo, which attrac...

$4.32M
USD